Tarlatamab (Imdelltra)

Key Messages

• Canada’s Drug Agency (CDA-AMC) recommends that Imdelltra be reimbursed by public drug plans for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients with disease progression on or after at least 2 prior lines of therapy including platinum-based chemotherapy if certain conditions are met.
• Imdelltra should only be covered to treat adult patients who have relapsed or refractory small cell lung cancer (SCLC), have received 2 or more lines of previous therapies (including 1 chemotherapy containing platinum and at least 1 other therapy), and who are in relatively good health. Imdelltra should not be covered for patients with untreated or symptomatic brain metastases.
• Imdelltra should only be reimbursed if administered in centres with appropriate medical support to manage potentially life-threatening adverse events, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), and if the cost of Imdelltra is reduced.